Commercial you Officer, this thank Founder call, Chief have the SADA begin quarter Officer, Business us for program for our Officer; and and updates Scientific Chief and Dr. Lisby, Officer, me call.
On everybody, today Financial reviewing morning, Chief Good Sue year our highlights sales platform. will Self-Assembly, today's Courtney. Chief our Radioimmunotherapy of Dr. Thomas by on with Chief or I I our on clinical portion and Q&A joining our you, Pretargeted DisAssembly Steen Gad, full and our Thank Officer, will XXXX global our Smith; utilizing us. our Rajah. Kruse; Vignesh and DANYELZA's join technology fourth Medical Bo
Sue provide then the our financial before XXXX we Next, Vigensh open will quarter. Q&A. full cash DANYELZA's in an our clinical our global year trials. of year line XXXX overview Bo updates report will the our fourth full further quarter into then our resources around and insights provide for sales and naxitamab performance, ongoing fourth will guidance
an was important Y-mAbs. year XXXX for
PRIT, in complemented plan driving based the revenue earlier novel and year, commercial SADA Radioimmunotherapy DANYELZA, Pretargeted on therapy, of emerged innovator differentiated our therapy by annual restructuring our an as development With completion Y-mAbs platform, radiopharmaceutical our antibody last growth.
by direct our million capital to $XX.X year in XX, patients SADA cash December only put to forefront proud our our to to neuroblastoma.
I'd all the dedication addition our do of cash the or clinical financial have employees. incredible relapsed made million of $XX.X cash very in advance more that of effective this in be and platform, equivalents day while sufficient in of In to possible, efforts XXXX, all as progress XXXX focused day we DANYELZA, we Y-mAbs With strategy resources members, reduced -- management believe cash and and continuing pipeline, we action. to treat our use who alongside out. as more a the I'm of full not high-risk at expand of remiss and PRIT They've our team hard they work global footprint and of the result our impacted mention geographic development work refractory patients
Now the key our and fourth let's dive into starting full XXXX, with highlights year quarter DANYELZA. for
or may bone marrow to the bone relapsed Neuroblastoma for who by anyone infants, partial cancer children. have or the is most cancer therapies. stable for For disease in the patients high-risk you prior response Y-mAbs, a be response, U.S. in with in third let treatment who or is demonstrated remind minor common me DANYELZA common of most refractory FDA the neuroblastoma approved newer that the
regions, of revenue million of approved achieving an continued XXXX in product DANYELZA which million. million XXXX. year The full adoption third finished This have an regions XXXX our recorded sales the was ex net remarkable to net XX% end $XX we the quarter, range guidance product compared DANYELZA $XX.X of We and an XX% on for U.S. indicates million, between and increasing DANYELZA the worldwide. achieved to of $XX.X was XXXX increase $XX fourth from Through pleased raised market near XX% an of of annual progress we of across quarter and top is are and of previously the a in XXXX. fourth accounts quarter note, what U.S. across increase of versus high-volume of in strong penetration increase
to accounts. continue in U.S. a with new of momentum gain We the number
in launch across of As XX active since sites accounts XX, initial U.S. XX added XXXX, with new DANYELZA's December the had XXXX. we
footprint through multiple to Our expand ex U.S. partnerships. continues
the from CMED. or price The DANYELZA Chamber, Medicines Brazilian well. in And Regulation Market launch is DANYELZA we progressing China the January, this for accepted
providing quarter coming partner in updates Adium, this launch in second look progress and forward Mexico this in Brazil and year the We anticipated to of with quarters. expect launch on DANYELZA our to the
Pharma children support Our we neuroblastoma of high-risk continuing is needs Clinical European early WEP relapsed/refractory progress in to access with the program with as Europe.
next and months. could Argentina receive potentially approval Kong in year submit plan in we this within ] to DANYELZA BLA addition, for Asia, In a [ additional XX the in Hong
geographic In forward look among to naxitamab multicenter to osteosarcoma investigating indication to in see year. II Kettering's progress Memorial with ISS sponsored in Sloan we trials its we expansion, expansion this addition of relapsed support the in particular, Phase ongoing continue readout trial naxitamab fourth our from of our quarter In patients strategy.
progress hear of ongoing more on about from will You trial naxitamab the call. the Vignesh later this
let PRIT to platform. Now shift our me SADA
related I stage therapies. I set provide administration of current Before programs, update commercialization, There of manufacturing moment key infrastructure a to the a around targeted our areas. lead to to brief on radiopharmaceutical want challenges X the and are take some
investment is there's made specialized the to radiopharmaceutical before that limited deliver a made. time therapy and and into is window, enormous Once therapy infrastructure manufacturing. where very radiopharmaceutical targeted released, it an There's currently ongoing First, patients manufacturing therapy which to expires. facilities,
which administer time. patients nuclear can is physician The Second is treatment radiopharmaceuticals, issue. With needs a prescribe been has current oncologist patient the participation, an removed journey traditionally oncologist that radiopharmaceuticals, to and or refer physician medicine always an at authorized to this essentially the physician. her his from
as therapy, there's continued are of is of to increasing we need demand administration radiopharmaceutical capable of radiopharmaceuticals. these able there for limited a drug radiopharmaceuticals. order limited the administer suites globe.
And across Third, sites number specialized issue in current handling fourth, number be theranostic the are and to an a shortages Right now,
As have delayed. shortages patient and build become care a referred to is reality, infrastructure manufacturers drug work the just to, I
these and solution SADA a a more and all at for PRIT will solve goal impact is have greatly physicians Our challenges provide simpler improved of care. patient to that efficient on
SADA We infusion We administer and offices, oncologist are PRIT in infrastructure process. freestanding within existing outpatient centers leveraging the centers. infusion a X-step centers,
the for in the imaging a centers. step, infusion a First, isotope be non-radioactive department can patient in Then can receive medicine or second licensed existing the nuclear SADA delivered centers.
are participation, to oncologists, increasing have physicians, infrastructure, specialists more engagement will we lead nuclear which we to we we Because the able leveraging and are and overall existing better believe medicine are physician with results.
agnostic. isotope be can PRIT SADA Importantly,
isotope long target as of the between SADA we the have on linkers will can As a and the utilize the to already diagnostic isotopes. multitude painted therapeutic is tumor, create ability we that and
in tumors, experience the the patient as time landscape. choose As infrastructure manufacturing, of very real decreased and increasing these about improve SADA we radiopharmaceutical and the to we're well PRIT while as potential expand toxicity to at around look activity administration treatment to different differentiators patients, ability to isotopes excited targeted and levels
lead to turn update brief let's Now our on programs. a
Phase GDX-SADA. I Our
in Part explores molecule, A X I single-arm And B and reminder, determines modified our a to is a X As treatment of cell X-week melanoma X Part safety XXXX. testing GDX-SADA the and It design. GDX-SADA cohort X repeat got intervals dosing solid the of is each and the be dose in I dose-limiting safety of GDX-positive for based by efficacy in and of a safety X, X lung X+X optimal to C initial dose the escalation dose or of tumors, dose important DOTA. after emphasize lutetium-XXX signs parts: and This payload. Phase Phase including protein using small toxicity, of patients days underway March tolerability trial period. so-called and finding cohort, evaluating study in multicenter patients observed will DLT between the that followed the evaluates malignant Part in dosing.
Dose on of sarcomas cancer, has escalation lutetium-XXX DOTA the
Part pleased trial are currently the are very in progressing. is We how with A and
cohort now advanced X X, and have through are cohorts We in X and dosing patients X.
active total Recall sites a of is sites. dosed plan the to the date. of patients profile safety Part X and protein radionuclide. the have deliver investigating to continue of currently time and determining that optimal additional have to We A We the trial adding XX the
not by scans what for are can believe necessarily the important of GDX-SADA have have no tumors. both and date, concept, experienced of to success ultimate patients namely and We the PK so It we a seen activity the find program. we development Based far. To that or are indicative the seen is toxicities. SPECT/CT have on encouraged to are very the full data we any that very, demonstrated results to have we complete this dose-limiting trials SADA bind of the and early note proof date, not
at data of second share I from to in of half A Phase study year. expect meeting We this medical the Part a this
Our SADA blood be plan This and non-Hodgkin's in plan patients T is which cell B first cancer. lymphoma we on lymphoma. CDXX in -- second SADA PRIT studied will focusing with our we SADA, first to program is to program which study
And planned program. our Our FDA. SADA IND by our the design comparable has Phase approved as see a you I can follows been GDX to here,
to are this enroll April sites on dose this trial in to expect patients in X first year. the We I and track Phase
treatment industry piquing differentiated radiopharmaceutical of has approach multiple We the the believe the a the at interest the cancers. inflection that targeted the We of and physicians novel to alike. radiopharmaceutical tumors potential and of huge and platform is blood solid truly potential patients point PRIT believe and choice SADA's delivery in become
pass year color will to call Smith sales I over provide Sue XXXX. for the to fourth and now Sue? the further DANYELZA U.S. on full quarter
